3/5
04:57 pm
otlk
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) [Yahoo! Finance]
Medium
Report
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) [Yahoo! Finance]
3/5
04:15 pm
otlk
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Medium
Report
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
2/19
09:00 am
otlk
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
Low
Report
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
2/18
08:13 am
otlk
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $0.50 price target on the stock.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $0.50 price target on the stock.
2/18
08:13 am
otlk
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $1.00 price target on the stock.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $1.00 price target on the stock.
2/17
08:05 am
otlk
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
High
Report
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
2/11
08:45 am
otlk
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
Medium
Report
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
1/6
08:35 am
otlk
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
Low
Report
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
1/5
08:33 am
otlk
Oncobiologics (NASDAQ:OTLK) had its price target lowered by analysts at Chardan Capital from $3.00 to $1.00. They now have a "neutral" rating on the stock.
High
Report
Oncobiologics (NASDAQ:OTLK) had its price target lowered by analysts at Chardan Capital from $3.00 to $1.00. They now have a "neutral" rating on the stock.
1/3
01:08 am
otlk
Oncobiologics (NASDAQ:OTLK) was downgraded by analysts at
Wall Street Ze
High
Report
Oncobiologics (NASDAQ:OTLK) was downgraded by analysts at
Wall Street Ze
12/28
08:12 pm
otlk
Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again [Seeking Alpha]
Medium
Report
Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again [Seeking Alpha]
12/26
07:07 pm
otlk
Outlook Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]
Medium
Report
Outlook Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]
12/26
05:00 pm
otlk
Outlook Therapeutics Announces New Employment Inducement Grants
Medium
Report
Outlook Therapeutics Announces New Employment Inducement Grants
12/22
08:02 am
otlk
Oncobiologics (NASDAQ:OTLK) had its price target raised by analysts at Ascendiant Capital Markets from $8.00 to $10.00. They now have a "buy" rating on the stock.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its price target raised by analysts at Ascendiant Capital Markets from $8.00 to $10.00. They now have a "buy" rating on the stock.
12/19
08:35 am
otlk
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 [Yahoo! Finance]
Medium
Report
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 [Yahoo! Finance]
12/19
08:05 am
otlk
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
Medium
Report
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
12/10
04:10 am
otlk
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.